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The reliable and precise evaluation of receptor–ligand interac-
tions and pair-interaction energy is an essential element of
rational drug design. While quantum mechanical (QM) methods
have been a promising means by which to achieve this, tradi-
tional QM is not applicable for large biological systems due to
its high computational cost. Here, the fragment molecular
orbital (FMO) method has been used to accelerate QM calcula-
tions, and by combining FMO with the density-functional tight-
binding (DFTB) method we are able to decrease computational
cost 1000 times, achieving results in seconds, instead of hours.
We have applied FMO-DFTB to three different GPCR–ligand sys-
tems. Our results correlate well with site directed mutagenesis
data and findings presented in the published literature, demon-
strating that FMO-DFTB is a rapid and accurate means of
GPCR–ligand interactions. VC 2017 Authors. Journal of Computa-
tional Chemistry Published by Wiley Periodicals, Inc.
DOI: 10.1002/jcc.24850
Introduction
The rationalization of potency and selectivity in the drug discov-
ery process requires an accurate understanding of the binding
interactions between a protein and its ligand.[1] However, visual
inspection and force-field-based molecular mechanics calcula-
tions (MM) cannot always explain the full complexity of the
molecular interactions, in particular CH-p, halogen-p, cation-p,
and nonclassical H-bonds, that play critical roles in receptor–
ligand binding.[2] The use of quantum mechanical (QM) methods
can take into account charge fluctuations and dynamic polariza-
tion, which are essential in assessing molecular interactions.
However, despite the many advantages that QM can bring, tradi-
tional QM methods are not feasible for large biological systems,
such as proteins, due to their high computational cost.
The FMO method[3] accelerates traditional QM methods, by
dividing the system into smaller pieces called fragments and
performing QM calculations on these fragments (Supporting
Information Fig. S1). FMO can be combined[4,5] with a fast QM
method, density-functional tight-binding (DFTB) approach.[6] A
key advantage of FMO is that it can provide the individual
contribution of each residue–ligand pair interaction energy
(PIE) to the total interaction energy (TIE). TIE is a sum of PIEs
for all residues; it is an estimate of the total protein-ligand
binding energy; whereas PIEs are residue contributions to it.
G-protein coupled receptors (GPCRs) are a large and well-
studied family of membrane proteins that comprise the targets
for about 30% of all pharmaceuticals currently on the market.[7,8]
There are over 800 GPCR proteins encoded in the human
genome, but drugs have only been developed against <10% of
these targets. Thus, there is huge potential to expand the
number of targets for which new therapies can be developed. To
develop new drugs, both for novel and for existing targets, it is
essential to understand at a molecular level the interactions that
take place between ligand and GPCR.
We previously illustrated[2] how the FMO-MP2 method can be
applied to several Class A GPCR–ligand crystal structures to
explore receptor–ligand interactions. In this communication, we
have extend our studies of receptor–ligand interactions by
selecting three of these cases and using them to establish the
reliability, speed and utility of FMO-DFTB in comparison with
FMO-MP2. MP2 is thus used as an established reference for vali-
dating DFTB. DFTB is based on a series expansion of electron
density and, as such, can be considered an approximation to
density functional theory (DFT).[6] The cost of performing MP2
calculations of fragments scales as N5, where N is the number of
basis functions in the fragment, due to the transformation of
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two-electron integrals. In contrast, the cost of DFTB is N3, two
orders of magnitude lower, due to the Fock matrix diagonaliza-
tion. Further, MP2 requires an expensive calculation of two-
electron integrals, and the cost of assembling the Fock matrix in
DFTB is low because it is parametrized. Finally, the FMO-specific
electrostatic embedding in DFTB uses point charges whereas
electron densities are used in MP2 calculations.
The three reference systems for this comparison are: (1)
BI167107 in complex with the human b2-Adrenoceptor (PDB
entry 3SN6)[9]; (2) JDTic in complex with the j-opioid receptor
(PDB entry 4DJH)[10]; and, (3) AZD1283 in complex with the
human P2Y12 receptor (PDB entry 4NTJ).[11] We selected these
systems because of the extensive structure activity relationship
(SAR) data available in the literature for these ligands (Sup-
porting Information Tables S2–S4). These analogs of the crystal
ligands were docked into the relevant receptors as described
previously[2] and the TIEs calculated by FMO-DFTB.
By performing calculations on a PC cluster with 32 CPU cores,
we have determined that FMO-DFTB is approximately 1000
times faster than the standard FMO-MP2 approach (Supporting
Information Table S1). FMO-DFTB calculations can be performed
in seconds, being practical for drug discovery projects.
The TIEs values calculated by FMO-DFTB can be compared
with the experimental ligand binding affinities (Fig. 1) and with
TIEs calculated with MP2 (Fig. 2). We observed a significant corre-
lation (r2 >0.66) between the calculated (TIEFMO-DFTB) and the
experimental values (Fig. 1). For 3SN6 and 4NTJ, we observed a
significant correlation (r2 >0.78) between the experimental val-
ues and the corresponding TIEs. In the case of 4DJH, the correla-
tion was lower (r250.66) and may have arisen as a consequence
of the large error margins observed in the experimentally mea-
sured data, as reported in the literature. The high correlation
between calculated and experimental values demonstrates that
FMO-DFTB provides a realistic assessment of TIE and offers addi-
tional insight into structure-based drug design for GPCR targets.
The TIE values computed using FMO-DFTB are in excellent
agreement (r2 >0.90) with the corresponding values calculated
using FMO-MP2 (Fig. 2), demonstrating that the performance of
FMO is not compromised by the speed obtained with FMO-
DFTB. To elaborate the comparison, atomic charges in MP2 and
DFTB are plotted in Supporting Information Figure S2. The good
correlation implies that the electrostatic interaction (a part of
PIE) in the two methods also correlates well; consistently with
the total PIEs, the electrostatic contribution, based on atomic
charges, is smaller in DFTB compared to MP2.
We used FMO-DFTB to calculate individual residue–ligand pair
interaction energies (PIEs) for the three systems (Fig. 3). We con-
sider any interaction with an absolute PIE 3.0 kcal/mol to be
significant. The water molecules in this work were extracted
from the crystal structures (if resolved) and treated explicitly to
explore their contribution to the receptor–ligand binding.
b2-Adrenoceptor receptor (b2AR) is primarily located in the
heart and the kidney, where it is involved in physiological pro-
cesses including the regulation of heart rate and blood pres-
sure. This first case was used to illustrate how the FMO-DFTB
results can be visualised, namely as a 3D figure (Fig. 3a) or
with the data displayed in a plot (Fig. 3b). FMO-DFTB detected
17 significant interactions in this system. The majority of these
interactions are consistent with literature reports[9] and with
those calculated at MP2 level.[2] Novel interactions with resi-
dues Val114 and Lys305 have been identified using FMO-DFTB.
While no information is available for Lys305, the mutation
from valine to alanine at Val114 has been reported[9] to dis-
rupt the binding of agonists and antagonists. According to
Figure 1. Correlation plots between experimentally measured affinity and TIEFMO-DFTB for 3 systems: a) 3SN6, b) 4DJH, and c) 4NTJ. Computationally
obtained values are shown on the y-axis and experimental values are shown on the x-axis. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2. Correlation plots between TIEFMO-MP2 (shown on the x-axis) and TIEFMO-DFTB (shown on the y-axis) for the three systems: a) 3SN6, b) 4DJH, and c)
4NTJ. [Color figure can be viewed at wileyonlinelibrary.com]
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this analysis, Val114 forms unusual CH-p bonds.[12] This result
is in agreement with our previous findings[2] where we exten-
sively explored the role of nonclassical interactions, such as
CH-p, in GPCR–ligand binding.
The opioid system controls pain, as well as reward and addic-
tive behaviours. Opioids exert their pharmacological actions
through activation of the three opioid receptors, l (MOR), d
(DOR), and k (KOR). JDTic is a long-acting (“inactivating”) antago-
nist of the KOR, and is highly selective for the l- and d- opioid
receptors and nociceptin receptor. The JDTic-KOR complex is the
first crystal structure of an opioid receptor.[10] FMO-DFTB calcula-
tions highlighted 23 strong interactions (Fig. 3c). These interac-
tions correlate well with the literature, where the selectivity of
JDTic has been rationalized by interactions with residues Val108
and Tyr312.[13] In addition, FMO-DFTB identified much stronger
interactions than those in the literature,[10] including that of
Asp138, highlighting the utility of this method for predicting res-
idues for further experimental study.
The P2Y12 receptor is considered to be one of the most promis-
ing drug targets for antiplatelet therapies. AZD1283 is a novel
P2Y12 antagonist for the treatment of arterial thrombosis and was
recently progressed into human clinical trials. FMO-DFTB identi-
fied 12 relevant interactions for this system (Fig. 3d). These results
are consistent with previous experimental findings.[11] The stron-
gest interaction identified is at Arg256, which is a residue shown
to interact with non-nucleotide antagonists.[14] Interestingly,
P2Y12 receptor signalling has been shown to be impaired in a
patient with an Arg to Gln mutation at position 256.[15]
We have demonstrated that FMO-DFTB is a rapid, accurate and
reliable method for the assessment of receptor–ligand interactions
and TIE calculations. The interactions detected by FMO-DFTB are
consistent with the experimental data and with those detected by
FMO-MP2.[2] The application of FMO-DFTB will be of great utility for
the design and evaluation of new compounds, providing a means
of significantly decreasing the effort and cost of chemical synthesis
needed for drug discovery programs.[16] The high correlation
between receptor-ligand experimentally evaluated affinity and
TIEFMO-DFTB indicates that FMO-DFTB can be used to determine the
binding affinities of new targets and, therefore, provides a means
of accurately predicting experimental outcomes.
Figure 3. FMO-DFTB results for (a) the human b2-Adrenoceptor in complex with BI167107 (PDB entry 3SN6). The carbon atoms of the ligand are shown in
light orange and the receptor residues are colored according to the PIE values calculated by FMO-DFTB (shown by the PIEDFTB bar in the lower right hand
corner of the panel. Nitrogen atoms are shown in blue, oxygen in red, sulphur in yellow and chlorine in light green. Sorted PIE values for GPCR residues
calculated at DFTB and MP2 levels (in green and yellow, respectively) are shown for the b2-adrenoceptor (b), the j-opioid receptor in complex with JDTic
(c), and the human P2Y12 receptor in complex with ASD1283 (d). [Color figure can be viewed at wileyonlinelibrary.com]
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For the first time, it is now possible to perform QM calculations
for protein-ligand complexes in a high throughput manner to
address the needs of processing large amounts of SAR data.
Docked ligands can be refined, rescored, and reranked with FMO-
DFTB in the presence of the surrounded protein and water mole-
cules. In summary, FMO-DFTB possesses the accuracy of much
more expensive methods (FMO-MP2) at a dramatically enhanced
speed, making it a very attractive method to support rational
SBDD against GPCR and other drug targets.
Computational Methods
We applied FMO code[17] version 5.1 distributed inside ab initio
quantum chemistry package GAMESS.[18] We used the third
order DFTB3 method[6] with 3ob parameters,[19,20] and the
Møller–Plesset second order perturbation theory (MP2) and, for
treating solvent effects, we combined both calculations with the
polarizable continuum model (PCM).[4] MP2 was used with the
6–31G* basis set whereas the UFF dispersion model was used for
DFTB3. The structures were taken from the previous study.[2]
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